Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Alzheimer’s Drug Maker Expects FDA Approval This Summer

FDA approval would expand Medicare coverage for the $26,500/year drug, but rollout could take years.

Lab Virus
Getty Images

According to a recent CNBC article, Japanese drugmaker Eisai expects the FDA to fully approve its Alzheimer's treatment Leqembi this summer. Leqembi, which was developed with Biogen, is an expensive new antibody that has shown promise in slowing the progression of Alzheimer's disease in people over the age of 65.  The company estimates that 100,000 people are expected to receive an early Alzheimer's diagnosis and become eligible for Leqembi by 2026, though the number of undiagnosed people is almost certainly higher.

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging